Human Papilloma Virus, Histopathological, and Molecular Subtyping in Penile Cancer: Relevance for Prognosis and Therapy Kerstin Junker, Sebastian Hölters,

Slides:

Advertisements

Similar presentations

Pascal Rischmann European Urology Supplements

Advertisements

Prostate Cancer 2008: Challenges in Diagnosis and Management

2004 World Health Organization Classification of the Noninvasive Urothelial Neoplasms: Inherent Problems and Clinical Reflections Rodolfo Montironi,

Renal Cell Carcinoma: Prognostic Factors and Patient Selection

Management of Acute and Chronic Retention in Men

Olivier Traxer European Urology Supplements

Tet Yap, Nicholas Watkin, Suks Minhas European Urology Supplements

Shock Wave Lithotripsy for Renal and Ureteric Stones

Bladder Cancer: Management and Future Directions

Who Benefits from Neoadjuvant or Adjuvant Hormone Therapy?

Shock Wave Lithotripsy for Renal and Ureteric Stones

Human papilloma viruses and cancer in the post-vaccine era

Martin C. Michel European Urology Supplements

Treatment of Advanced and Metastatic Renal Cancer: A Revolution?

Bladder Cancer: A Major Public Health Issue

What is New in Bladder Cancer Diagnosis and Management?

The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.

Back to the Future: Introduction and Conclusions

What is New in Hormone Therapy for Prostate Cancer in 2007?

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

Vulvar Lichen Sclerosus: Diagnosis and Management

Multiple aggressive squamous cell carcinomas associated with prolonged voriconazole therapy in four immunocompromised patients O. Epaulard, C. Saint-Raymond,

Infectious causes of cancer: an evolving educational saga

Counselling the Prostate Cancer Patient

Laurent Boccon-Gibod European Urology Supplements

Molecular Tumour Profiling for Detection of Biomarkers in Renal Cell Tumours Kerstin Junker, Jimsgene Sanjmyatav, Joerg Mueller, Thomas Steiner, Heiko.

Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward? Michel Bolla European.

An Update of Current Practice in Hypospadias Surgery

APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26

Richard C. Harkaway European Urology Supplements

Tyrosine Kinase Inhibitors in Clinical Practice: Patient Selection

Tim Schneider European Urology Supplements

Optimal Control of Testosterone: A Clinical Case-Based Approach of Modern Androgen- Deprivation Therapy Bertrand Tombal, Richard Berges European Urology.

The Importance of Testosterone Control in Prostate Cancer

Bone Health in Patients With Prostate Cancer: Monitoring and Diagnosis

Volume 26, Issue 2, Pages (February 2018)

Jacques Irani European Urology Supplements

Insights into the Relationships between Prostatic Disorders and Their Potential Impact on Future Urologic Practice Claus Roehrborn European Urology.

Neal Shore European Urology Supplements

Kidney Cancer: Highlights from 2006

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

Sergio Bracarda European Urology Supplements

Christian Stief European Urology Supplements

Bisphosphonates Can Prevent Skeletal Complications of Malignant Bone Disease from Prostate Cancer and Renal Cell Carcinoma Fred Saad European Urology.

New Trends in Managing the Prostate Cancer Patient

Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders

Emmanuel Chartier-Kastler, Kate Davidson European Urology Supplements

A Multidisciplinary Team Approach for the Optimal Clinical Management of Metastatic Hormone-Refractory Prostate Cancer—Case Study John Fitzpatrick European.

Prostate Cancer 2008: Challenges in Diagnosis and Management

How Do New Data from Clinical Trials Allow Us to Optimise the Assessment and Treatment of Patients with Benign Prostatic Hyperplasia? Vincenzo Mirone

Axel Heidenreich European Urology Supplements

847. Eradication of Therapy-Resistant Human Prostate Tumors Using an Ultrasound Guided Site-Specific Cancer Terminator Virus Delivery Approach Molecular.

Improving Flexibility and Quality of Life for Your Patients: A Must?

Profile of Silodosin European Urology Supplements

Volume 143, Issue 6, (December 2010)

Epidemiology, Pathogenesis, and Pathophysiology of Urolithiasis

The Increasing Responsibility of the Urologist in Maintaining Bone Health in Prostate Cancer Patients Kurt Miller European Urology Supplements Volume.

Prognostic Factors in Non–Muscle-Invasive Bladder Tumors

Early Single-Instillation Chemotherapy Has No Real Benefit and Should Be Abandoned in Non–Muscle-Invasive Bladder Cancer Sten Holmäng European Urology.

Clinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma Jan Roigas European Urology Supplements Volume.

In This Issue Molecular Therapy Volume 16, Issue 4, (April 2008)

Joaquim Bellmunt European Urology Supplements

The Impact of Premature Ejaculation on Partners and Relationships

Oncoforum Urology: Prostate Cancer 2008 at a Glance

Epidemiology and Demographics of Prostatitis

Jan Roigas European Urology Supplements

Axel Heidenreich European Urology Supplements

Pathology and Molecular Pathogenesis of Renal Cell Carcinoma

Kiran H. Lagisetty, David G. Beer, Andrew C. Chang

Volume 51, Issue 5, Pages (May 2007)

Presentation transcript:

Human Papilloma Virus, Histopathological, and Molecular Subtyping in Penile Cancer: Relevance for Prognosis and Therapy Kerstin Junker, Sebastian Hölters, Arndt Hartmann European Urology Supplements Volume 16, Issue 12, Pages 295-300 (December 2017) DOI: 10.1016/j.eursup.2017.09.003 Copyright © 2017 European Association of Urology Terms and Conditions

Fig. 1 Subtypes of squamous cell carcinoma with strong correlation to human papilloma virus (HPV) infection (World Health Organization 2016). (A) Squamous cell carcinoma, usual type, HPV negative. (B) Pseudohyperplastic carcinoma, HPV negative in a patient with chronic lichen sclerosus (insert). (C) Verrucous carcinoma, HPV negative, typical bulbous shape of the invasion front (insert). (D) Warty carcinoma, HPV positive. (E) Basaloid squamous cell carcinoma, HPV positive. (F) Warty-basaloid carcinoma, HPV positive. European Urology Supplements 2017 16, 295-300DOI: (10.1016/j.eursup.2017.09.003) Copyright © 2017 European Association of Urology Terms and Conditions